ESR1 and cancer: Furthermore, preliminary comparisons of the parenchymal patterns of estrogen-receptor positive (ER+) and negative (ER–) cancer cases measured with the same methodology [51] showed that subtype-specific breast cancer risk assessment based on mammographic textures may also be feasible [79].